Premium
No association between HER‐2 gene polymorphism at codon 655 and a risk of bladder cancer
Author(s) -
Wang Lizhong,
Habuchi Tomonori,
Takahashi Takeshi,
Kamoto Toshiyuki,
Zuo Tao,
Mitsumori Kenji,
Tsuchiya Norihiko,
Sato Kazunari,
Ogawa Osamu,
Kato Tetsuro
Publication year - 2001
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.10129
Subject(s) - genotype , bladder cancer , odds ratio , transitional cell carcinoma , confidence interval , medicine , gastroenterology , oncology , breast cancer , biology , cancer , gene , genetics
The amplification and overexpression of the human epidermal growth factor receptor 2 gene HER‐2 (also known as c‐erb‐B2 or neu ) have been shown to be associated with bladder cancer and its progression. Recent studies indicated an association between the Ile to Val polymorphism at codon 655 of HER‐2 and susceptibility to breast cancer. To investigate the correlation between the Ile/Val polymorphism and the susceptibility and progression of bladder cancer, we analyzed the polymorphism in 232 patients with transitional cell carcinoma of the bladder and 408 normal controls. The frequencies of the Ile/Ile, Ile/Val and Val/Val genotype were 75.9%, 21.6% and 2.6%, respectively, in patients with bladder cancer and 75.7%, 23.0% and 1.2%, respectively, in controls. Statistical analyses of the genotype prevalence showed no significant difference between bladder cancer patients and normal controls ( p = 0.419). Moreover, no significant differences in the genotype prevalence were observed when the patients were stratified according to the tumor grade, stage and smoking habits. When the Ile/Ile genotype was compared to the Ile/Val and Val/Val genotypes, a significant difference was found only between the patients with tumor stage Ta and those with T1‐4 (age, gender and smoking habits‐adjusted odds ratio = 2.13, 95% confidence interval = 1.09–4.15, p = 0.027). When the Ile/Ile + Ile/Val genotypes compared to the Val/Val genotype, no significant findings were observed. These results suggested that the HER‐2 polymorphism at codon 655 is unlikely to be associated with the onset of bladder cancer. Furthermore, the findings suggest no association between this polymorphism and the disease progression in bladder cancer, although the possibility remains that the Ile/Ile genotype may be related to an increased risk of disease progression. © 2001 Wiley‐Liss, Inc.